VCYT
Veracyte, Inc.
Diagnostics & Research · Healthcare · United States
42.60
close · 2026-08-13
value
52
cheaper than peers52
quality
89
stronger fundamentals89
ranked against
Diagnostics & Research
value
quality
28 peers
Value inputs
| measure | company | vs peers |
| price to book | 2.58× | 83 |
| forward P/E | 21.87× | 66 |
| EV to EBITDA | 27.84× | 32 |
| price to sales | 6.64× | 31 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.9% | 94 |
| operating margin | 15.3% | 69 |
| return on equity | 8.8% | 60 |
| revenue growth | 15.5% | 59 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | $106.2M |
| employees | 755 |
| first trade | 2013-10-30 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-08-04 |